A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Evolving pharmacovigilance requirements with novel vaccines and vaccine components
BMJ Global Health
This paper explores the pipeline of new and upcoming vaccines as it relates to monitoring their safety. Compared with most currently available vaccines, that are constituted of live attenuated organisms or inactive products, future vaccines will also be based on new technologies. Several products that include such technologies are either already licensed or at an advanced stage of clinical development. Those include viral vectors, genetically attenuated live organisms, nucleic acid vaccines,doi:10.1136/bmjgh-2020-003403 pmid:34011500 fatcat:hmz7prbfbrf3ppamwkw7vvuhxy